<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227678</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2764</org_study_id>
    <nct_id>NCT04227678</nct_id>
  </id_info>
  <brief_title>Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency</brief_title>
  <acronym>AGL12</acronym>
  <official_title>Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipoprotein lipase (LPL) is an enzyme that plays an important role in removing triglycerides&#xD;
      (TG) (molecules that transport dietary fat) from the blood. Patients with LPL deficiency&#xD;
      (LPLD) display during their whole life very high plasma TG levels often associated with&#xD;
      episodes of postprandial abdominal pain, malaise, blurred vision, dizziness&#xD;
      (hyperchylomicronemia syndrome) that may lead to recurrent pancreatitis episodes. Because of&#xD;
      their very slow clearance in blood of their chylomicron-TG, these patients need to severely&#xD;
      restrict their dietary fat intake to avoid these complications. Fortunately, novel treatments&#xD;
      are being developed to circumvent LPL deficiency (LPLD) metabolic effect on chylomicron-TG&#xD;
      clearance. However, there is no data on how LPLD affect organ-specific dietary fatty acid&#xD;
      metabolism nor how the novel therapeutic agents may change this metabolism. For example, it&#xD;
      is currently not understood how subjects with LPLD store their DFA into adipose tissues and&#xD;
      whether they are able to use DFA as a fuel to sustain their cardiac metabolism, as healthy&#xD;
      individuals do. This study aims to better understand theses two questions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol includes 3 visits: the screening visit and 2 postprandial metabolic&#xD;
      studies performed in random order at an interval of 7 to 14 days, and performed with (A1) and&#xD;
      without (A0) an intravenous (i.v.) heparin bolus followed by 250 IU/h i.v during 6 hours.&#xD;
      Each metabolic study will last 9 hours (with 6 hours postprandial) and will include PET and&#xD;
      stable isotopic tracer methods. At time 0, a low fat liquid meal will be ingested over 20&#xD;
      minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ-specific Dietary Fatty Acid (DFA) partitioning</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using oral administration of [18F ]-Fluoro-6-Thia- Heptadecanoic Acid (FTHA ) during whole-body acquisition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial DFA uptake</measure>
    <time_frame>2 months</time_frame>
    <description>will be assessed using oral administration of [18F]-FTHA during dynamic PET acquisition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial nonesterified fatty acids (NEFA) metabolism</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using [11C]-palmitate during dynamic PET acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary fatty acid oxidation rate</measure>
    <time_frame>6 months</time_frame>
    <description>will be measured using breath [13C]-carbon dioxide enrichment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total oxidation rate</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial plasma NEFA turnover</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined using stable isotope tracers of fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial plasma glucose turnover</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined using stable isotope tracers of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function by Positron Emitting Positron (PET) ventriculography</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using [11C]-acetate PET/CT. 180 megabecquerel (MBq) will be administered by bolus injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial oxidative metabolism</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using i.v. [11C]-acetate during dynamic PET/CT scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined using a multiplex ELISA which will measure multiple analytes in a single experiment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver nonesterified fatty acids (NEFA) metabolism</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using [11C]-palmitate during dynamic PET acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites distribution in plasma</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using oral administration of [18F]-FTHA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Lipoprotein Lipase Deficiency</condition>
  <arm_group>
    <arm_group_label>Control group- A0</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group: Healthy subjects with fasting glucose &lt; 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose &lt; 7.8 mmol/l and HbA1c &lt; 5.8%; fasting TG &lt; 1.5 mmol/l);&#xD;
A0: without heparin administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPLD group-A0</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LPLD group: LPL deficient subjects with history of fasting TG &gt; 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;&#xD;
A0: without heparin administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group-A1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group: Healthy subjects with fasting glucose &lt; 5.6, 2-hour post 75g OGTT glucose &lt; 7.8 mmol/l and HbA1c &lt; 5.8%; fasting TG &lt; 1.5 mmol/l);&#xD;
A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPLD group-A1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LPLD group: LPL deficient subjects with history of fasting TG &gt; 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;&#xD;
A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal</description>
    <arm_group_label>Control group-A1</arm_group_label>
    <arm_group_label>LPLD group-A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>liquid meal</intervention_name>
    <description>low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes</description>
    <arm_group_label>Control group- A0</arm_group_label>
    <arm_group_label>Control group-A1</arm_group_label>
    <arm_group_label>LPLD group-A0</arm_group_label>
    <arm_group_label>LPLD group-A1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  8 healthy LPL-deficient individuals (LPLD subjects) with history of fasting TG &gt; 5&#xD;
             mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;&#xD;
&#xD;
          -  8 control subjects (fasting glucose &lt; 5.6, 2-hour post 75g OGTT glucose &lt; 7.8 mmol/l&#xD;
             and HbA1c &lt; 5.8%; fasting TG &lt; 1.5 mmol/l);&#xD;
&#xD;
          -  age 18 to 75 yo;&#xD;
&#xD;
          -  To be willing and able to adhere to the specifications of the protocol;&#xD;
&#xD;
          -  To have signed an informed consent document indicating that they understood the&#xD;
             purpose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 yo;&#xD;
&#xD;
          -  overt cardiovascular disease as assessed by medical history, physical exam, and&#xD;
             abnormal ECG&#xD;
&#xD;
          -  Treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to&#xD;
             affect lipid or carbohydrate metabolism (except statins, metformin, and other&#xD;
             antihypertensive agents that can be safely interrupted);&#xD;
&#xD;
          -  Treatment with anti-hypertensive medication (only for LPL-deficient individuals);&#xD;
&#xD;
          -  presence of liver or renal disease; uncontrolled thyroid disorder;&#xD;
&#xD;
          -  previous diagnosis of heparin-induced thrombocytopenia;&#xD;
&#xD;
          -  Treatment with oral anticoagulation medication or platelet aggregation inhibiting&#xD;
             drugs;&#xD;
&#xD;
          -  A history of major hemorrhagic event;&#xD;
&#xD;
          -  smoking (&gt;1 cigarette/day) and/or consumption of &gt;2 alcoholic beverages per day;;&#xD;
&#xD;
          -  Female of child-bearing potential who is pregnant, breast feeding or intends to become&#xD;
             pregnant or pre-menopausal female with a positive serum pregnancy test at the time of&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Carpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique Frisch</last_name>
    <phone>819-346-1110- ext12394</phone>
    <email>frederique.frisch@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Frisch</last_name>
      <phone>819-346-1110- ext12394</phone>
      <email>frederique.frisch@usherbrooke.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>tenured professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

